Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

7.840 +0.040 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cullinan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
Expert Ratings for Cullinan Oncology
Via Benzinga
Why Shares of Cullinan Oncology Jumped This Week
The company's presentation at a conference got the attention of analysts and investors. 
Via The Motley Fool
4 Analysts Have This to Say About Cullinan Oncology
Via Benzinga
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
What 4 Analyst Ratings Have To Say About Cullinan Oncology
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Insiders Buy Around $15M Of 2 Stocks
Although the Dow Jones dropped by around 350 points on Friday, there were a few notable insider trades. 
Via Benzinga
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of... 
Via Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
A Look Into Healthcare Sector Value Stocks
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Short Volatility Alert: Cullinan Oncology
On Monday, shares of Cullinan Oncology, Inc. (NASDAQ: CGEM) experienced volatile short activity. After the activity, the stock price went up at 2.45% to $10.88. The overall... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Are Cullinan Oncology Shares Rising Today?
Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. 
Via Benzinga
Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting
Cullinan Oncology Inc (NASDAQ: CGEM)  
Via Benzinga
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Down 200 Points; Dutch Bros Shares Plunge
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Executives Buy Around $15M Of 4 Stocks
Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering. 
Via Benzinga
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial... 
Via Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 111 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Citigroup (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.